Research programme: virus vaccines - Crucell/National Institutes of Health

Drug Profile

Research programme: virus vaccines - Crucell/National Institutes of Health

Latest Information Update: 03 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell; National Institutes of Health (USA)
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ebola virus infections; Lassa fever; Marburg virus disease

Most Recent Events

  • 03 Oct 2013 Preclinical development is ongoing in the US
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 03 Oct 2008 Crucell receives a $US30 million funding contract from the National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH) for the development of a vaccine for Marburg and Ebola virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top